JNJ•benzinga•
Johnson & Johnson's Nipocalimab Achieves Over 77% IgG Reduction And Significant Clinical Improvement In Phase 2 Sjögren's Disease Study; Gains FDA Breakthrough Therapy Designation
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 14, 2024 by benzinga